Drugs / LY4100511
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06916143 | Apr 2025 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT06627088 | Aug → Dec 2024 | — | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06503679 | Jul → Dec 2024 | — | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06345794 | Apr → Jun 2024 | — | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06311656 | Mar → Oct 2024 | — | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06937411 | Feb → Oct 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06602219 | Oct 2024 → Jul 2025 | psoriasis | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4100511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06602219 ↗ |
| Known as | DC-853 | “A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants” NCT06311656 ↗3“LY4100511 (DC-853) administered orally alone then LY4100511 (DC-853) administered orally with Rabeprazole.” NCT06916143 ↗ “LY4100511 (DC-853) Dose 1” NCT06503679 ↗ “LY4100511 (DC-853)” NCT06627088 ↗ |
| Known as | DICE-853 | “The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853)...” NCT06345794 ↗ |
| Route | Oral | “administered orally” NCT06311656 ↗ |